Author Affiliations: Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California.
Goldberg LH, Firoz BF, Weiss GJ, Blaydorn L, Jameson G, Von Hoff DD. Basal cell nevus syndrome: a brave new world. Arch Dermatol. 2010;146(1):17-19.
While most basal cell carcinomas (BCCs) are amenable to resection, surgical intervention is impractical for patients with metastatic or locally invasive BCCs or cancer predisposition syndromes, such as basal cell nevus syndrome. Until now, treatments for these nonsurgical candidates met with limited efficacy. The causal role of aberrant hedgehog signaling in BCCs has led to the recent exploration of hedgehog pathway inhibitors as a targeted therapy, and, as shown by Goldberg et al last year, the smoothened antagonist GDC-0449 [2-chloro-N- (4-chloro-3-[pyridin-2-yl]phenyl)-4-(methylsulfonyl)benzamide] can achieve clinical regression in basal cell nevus syndrome. Since Goldberg and colleagues' article was published, GDC-0449 has demonstrated efficacy against advanced BCCs and metastatic medulloblastoma, and hedgehog pathway inhibitors are currently under clinical investigation for several other lethal cancers. Hedgehog pathway inhibitors offer a new adjuvant medical therapy for advanced and, if trials demonstrate effectiveness, early-stage BCCs.
From August 2009, through August 2010, this article was viewed 1858 times on the Archives of Dermatology Web site.
Contact Dr Oro at Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305 (oro@stanford.edu).
Financial Disclosure: The authors have participated in a Genentech-sponsored trial for GDC-0449.
This article was corrected for errors on October 17, 2011.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Dermatology editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.